Characteristics and results following nonmyeloablative HCT (N = 52 patients receiving allografts)
. | No. . | % or range . |
|---|---|---|
| Days from auto to allograft, median | 62 | 40-299 |
| Donor age, median y | 50 | 31-73 |
| Number CD34 cells × 106 kg, median | 8.5 | 2.0-28.0 |
| Number CD3 cells × 108 kg, median | 3.5 | 1.41-11.73 |
| Granulocyte nadir, median cells/μL | 760 | 100-3 184 |
| Days granulocyte counts less than 500/μL, median | 0 | 0-1 |
| Platelet nadir, median cells/μL | 95 000 | 15 000-192 000 |
| Days platelet counts less than 20 000/μL, median | 0 | 0-1 |
| Number of platelet transfusions, median | 0 | 0-140 |
| Number RBC transfusions, median | 0 | 0-40 |
| Days hospitalized, median | 0 | 0-37 |
| GVHD | ||
| Acute GVHD II-IV | 20/52 | 38.5% |
| Grade I | 16/52 | 30.8% |
| Grade III | 1/52 | 1.9% |
| Grade IV | 3/52 | 5.8% |
| Chronic GVHD | 32/50 | 64% |
| Chronic extensive GVHD | 23/50 | 46% |
. | No. . | % or range . |
|---|---|---|
| Days from auto to allograft, median | 62 | 40-299 |
| Donor age, median y | 50 | 31-73 |
| Number CD34 cells × 106 kg, median | 8.5 | 2.0-28.0 |
| Number CD3 cells × 108 kg, median | 3.5 | 1.41-11.73 |
| Granulocyte nadir, median cells/μL | 760 | 100-3 184 |
| Days granulocyte counts less than 500/μL, median | 0 | 0-1 |
| Platelet nadir, median cells/μL | 95 000 | 15 000-192 000 |
| Days platelet counts less than 20 000/μL, median | 0 | 0-1 |
| Number of platelet transfusions, median | 0 | 0-140 |
| Number RBC transfusions, median | 0 | 0-40 |
| Days hospitalized, median | 0 | 0-37 |
| GVHD | ||
| Acute GVHD II-IV | 20/52 | 38.5% |
| Grade I | 16/52 | 30.8% |
| Grade III | 1/52 | 1.9% |
| Grade IV | 3/52 | 5.8% |
| Chronic GVHD | 32/50 | 64% |
| Chronic extensive GVHD | 23/50 | 46% |
GVHD indicates graft-versus-host disease.